Skip to content

Peptides for ADHD: What Semax, Selank and Dihexa Evidence Shows

Peptides for ADHD: Semax's one ADHD paper is a theory, not a trial. Selank and dihexa have zero ADHD studies. What is actually FDA-approved for ADHD.

Sebastian Hunter, Founder and EditorWritten bySebastian Hunter, Founder and EditorI'm a 42-year-old senior advisor and distance runner who came to peptides as a sceptic. I'm not a doctor: I read the research, run my own experiment and keep honest notes. Read full bio

The short version

No peptide is approved to treat ADHD, and ADHD already has FDA-approved stimulant and non-stimulant medication. Semax's only documented ADHD connection is a 2007 theoretical paper reasoning from rodent data, not a clinical trial. Selank and dihexa have no published ADHD research of any kind. The closest human data is a small 2026 pilot trial of intranasal oxytocin in 8 children. It measured theory-of-mind, not core ADHD symptoms.

  • No peptide holds FDA approval for ADHD. Stimulant and non-stimulant medications do.
  • Semax's ADHD link is one 2007 hypothesis paper reasoning from rodent data, not a clinical trial.
  • Selank and dihexa have zero published studies of any kind in ADHD.
  • A tiny 2026 pilot trial (n=8) tested oxytocin alongside stimulant medication on theory-of-mind in ADHD, not core symptoms.
  • Dihexa's own foundational rat memory paper carries a published expression of concern.

No peptide is approved to treat ADHD, and none has a completed clinical trial showing it does. Semax, Selank and dihexa are all marketed in the nootropic space for focus and attention. ADHD is the condition that marketing gestures toward without naming. This page reports what has and has not been tested, compound by compound. ADHD already has FDA-approved medication that has been through that process.

Does any peptide treat ADHD?

No. This page could not locate a completed clinical trial of Semax, Selank or dihexa treating ADHD. One theoretical paper proposes Semax as a candidate. One small pilot trial tested oxytocin on a narrow social-cognition measure, not core symptoms. Nothing here amounts to a demonstrated ADHD treatment.

Semax and ADHD: one hypothesis paper, not a trial

A 2007 paper Tsai 2007 - Tsai SJ. Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome. Med Hypotheses. 2007;68(5):1144-6., in the references below in the journal Medical Hypotheses proposes that Semax “may have good therapeutic potential in ADHD.” That journal publishes speculative, unproven ideas rather than original research. The reasoning draws entirely on rodent studies: Semax augmented the effect of psychostimulants on dopamine release and stimulated BDNF synthesis in animals.

The paper is a single author’s hypothesis for future research. It does not report Semax being given to a single person with ADHD. See the full Semax guide for what has been tested in humans: motor neuron disease and stroke rehabilitation, neither one ADHD.

Selank and dihexa: no ADHD research at all

A direct PubMed search for Selank combined with ADHD or attention deficit returns zero results. Selank’s real evidence sits in generalized anxiety disorder and neurasthenia, a different condition entirely.

Dihexa returns zero results for the same ADHD search. Its only animal data comes from one foundational paper McCoy 2013 - McCoy AT, Benoist CC, Wright JW et al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. J Pharmacol Exp Ther. 2013;344(1):141-54., in the references below. That paper tested dihexa in aged rats and in rats given scopolamine to impair memory, a model of Alzheimer’s-type memory loss, not attention or hyperactivity. The paper itself now carries a published expression of concern from its own journal Anon 2021 - Anon. Notice of Concern: McCoy AT, Benoist CC, Wright JW, Kawas LH, Bule-Ghogare JM, Zhu M, Appleyard SM, Wayman GA, and Harding JW (2013) Evaluation of Metabolically Stabilized Angiotensin IV Analogs as Procognitive/Antidementia Agents, J Pharmacol Exp Ther, 344: 141-154; DOI: https://doi.org/10.1124/jpet.112.199497. J Pharmacol Exp Ther. 2021;378(3):313., in the references below. No published human trial of dihexa exists for any use; see the full dihexa guide for detail.

Oxytocin and ADHD: one small pilot trial

A 2026 pilot, proof-of-concept randomized controlled trial Saker 2026 - Saker T, Blechman S, Dror C et al. The effect of intranasal oxytocin on theory of mind in children with attention deficit/hyperactive disorder. J Psychiatr Res. 2026;192:95-99., in the references below gave 8 children with ADHD a single dose of intranasal oxytocin or placebo in a double-blind crossover design. In a second phase, they received oxytocin alongside their prescribed stimulant medication.

The trial measured theory-of-mind, social cognition and executive-function tasks. It did not measure the core ADHD symptoms of inattention, hyperactivity or impulsivity that a diagnosis is based on. It reports improved reaction time and response consistency on the social-cognition tasks after oxytocin, with no adverse effects. The authors call the result preliminary and say larger trials are needed.

What is FDA-approved for ADHD

Stimulant medications are FDA-approved for ADHD. Methylphenidate’s own FDA label states it is indicated for the treatment of Attention Deficit Hyperactivity Disorder in patients 6 years and older. Non-stimulant medications are also FDA-approved for ADHD. None of them is a peptide, and none of the compounds on this page has been through that same review.

Common questions

Can peptides treat ADHD?

No peptide has FDA approval for ADHD, and this page could not locate a completed clinical trial showing any peptide treats it. Semax has a single theoretical paper proposing it as a candidate. Selank and dihexa have no ADHD research at all. A small pilot trial tested oxytocin on a narrow social-cognition measure, not core ADHD symptoms.

Does Semax help ADHD?

This has not been tested in a clinical trial. A 2007 paper in the journal Medical Hypotheses proposed that Semax could be a candidate treatment for ADHD. It reasoned from rodent studies showing Semax affects dopamine release and BDNF. The paper is a theoretical hypothesis, framed as a proposal for future research. It does not report Semax being given to anyone with ADHD.

Is there research on Selank for ADHD?

No. A direct PubMed search for Selank combined with ADHD or attention deficit returns zero results. Selank's actual trial record, covered on its own page, is in generalized anxiety disorder and neurasthenia, an unrelated area.

Does dihexa help focus or ADHD?

No study has tested dihexa in ADHD or any attention-deficit model, and a direct search returns zero results. Dihexa's only animal data concerns memory in aged and scopolamine-impaired rats. That is a different domain (Alzheimer's-type memory loss, not attention). Even that foundational paper carries a published expression of concern from its own journal. No published human trial of dihexa exists for any use.

Does oxytocin help ADHD?

One small pilot trial exists. Eight children with ADHD received a single dose of intranasal oxytocin or placebo in a crossover design, then oxytocin alongside their prescribed stimulant medication. The trial measured theory-of-mind and social-cognition tasks, not core ADHD symptoms like inattention or hyperactivity. It reported improved reaction time and consistency on those tasks, with no adverse effects. The authors call it preliminary and say larger trials are needed.

What is the FDA-approved treatment for ADHD?

Stimulant medications, such as methylphenidate, are FDA-approved for ADHD. Methylphenidate's own FDA label states it is indicated for the treatment of Attention Deficit Hyperactivity Disorder. Non-stimulant medications are also FDA-approved for ADHD. None of them is a peptide.

References (7 sources)

Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.

  1. 1.Tsai SJ. Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome. Med Hypotheses. 2007;68(5):1144-6.StudyPMID 16996699
  2. 2.Saker T, Blechman S, Dror C et al. The effect of intranasal oxytocin on theory of mind in children with attention deficit/hyperactive disorder. J Psychiatr Res. 2026;192:95-99.Randomised trialPMID 41138507
  3. 3.McCoy AT, Benoist CC, Wright JW et al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. J Pharmacol Exp Ther. 2013;344(1):141-54.StudyPMID 23055539full text
  4. 4.Anon. Notice of Concern: McCoy AT, Benoist CC, Wright JW, Kawas LH, Bule-Ghogare JM, Zhu M, Appleyard SM, Wayman GA, and Harding JW (2013) Evaluation of Metabolically Stabilized Angiotensin IV Analogs as Procognitive/Antidementia Agents, J Pharmacol Exp Ther, 344: 141-154; DOI: https://doi.org/10.1124/jpet.112.199497. J Pharmacol Exp Ther. 2021;378(3):313.StudyPMID 34551989
  5. 5.FDA label (DailyMed) for methylphenidate hydrochloride extended-release capsules - indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Fetched this session.- DailyMed, US National Library of Medicinelabel
  6. 6.NCBI E-utilities esearch: Selank AND (ADHD OR attention deficit), zero records (queried 2026-09-27).- National Center for Biotechnology Information, US National Library of Medicinedatabase
  7. 7.NCBI E-utilities esearch: dihexa AND (ADHD OR attention deficit), zero records (queried 2026-09-27).- National Center for Biotechnology Information, US National Library of Medicinedatabase

Keep reading

Related guides